YOU ARE DOWNLOADING DOCUMENT

Please tick the box to continue:

Transcript
Page 1: Neuropharmacology: Affective Disorders

Affective Disorders

Brian J. Piper, Ph.D., M.S.

Page 2: Neuropharmacology: Affective Disorders

Goals

• Serotonin (5-HT)• Major Depressive Disorder• Bipolar Disorder

Page 3: Neuropharmacology: Affective Disorders

Major Depressive Disorder

• Five + (1 or 2) causing significant social or occupational impairment not due to medical condition– 1) Depressed mood most of the day, nearly every day– 2) Marked diminished interest or pleasure, in activities– 3) Significant weight loss/gain (+5%/month)– 4) Insomnia/hypersomnia– 5) Fatigue or loss of energy– 6) Diminished ability to think or concentrate– 7) recurrent thoughts of death, suicidal attempt/plan

Anna M. Kring, Ph.D. Lecture 14, 19:38-23:08

Page 4: Neuropharmacology: Affective Disorders

Edvard Munch (1863-1944)

Despair (1894)

Vincent van Gogh (1853-1890)

Sorrowing Old Man (‘At Eternity’s Gate’)1890

Page 5: Neuropharmacology: Affective Disorders

MDD

• Episode = 6 months• Female: Males (2:1)• Age of Onset (younger)

Page 6: Neuropharmacology: Affective Disorders

Heritability

BMJ 1999; 319 : 37

Page 7: Neuropharmacology: Affective Disorders

Biosynthesis

HO: hydroxylCOOH: carboxyl

Page 8: Neuropharmacology: Affective Disorders

Biosynthesis

Tryptophan: yogurt, milk, fish, nuts

Tryptophan hydroxylase: rate limitingstep

Page 9: Neuropharmacology: Affective Disorders
Page 10: Neuropharmacology: Affective Disorders

Role of 5-HT in MDD

• Methods: 15 un-medicated women with a history of 2+ episodes of depression were on a low protein diet for 1 week, then randomly assigned to receive:– Tryptophan + : L-tryptophan (1.9 g), L-alanine (4.6

g) L-arginine (4.1 g)

– Tryptophan - : L-alanine (4.6 g) L-arginine (4.1 g)

Page 11: Neuropharmacology: Affective Disorders

Hamilton Depression Inventory

http://www.psy-world.com/online_hamd.htm

Page 12: Neuropharmacology: Affective Disorders

Ham-D

http://www.psy-world.com/online_hamd.htm

Max Hamilton

1912-1988

Page 13: Neuropharmacology: Affective Disorders

Smith et al. (1997). Lancet, 349, 915-919.

Page 14: Neuropharmacology: Affective Disorders

Smith et al. (1997). Lancet, 349, 915-919.

Page 15: Neuropharmacology: Affective Disorders

5-HT & Aggression

• Para-chlorophenylalanine (PCPA): irreversible tryptophan hydroxylase inhibitor

• PCPA treated rats were tested for muricide

Killers Non-killers

Control 0 13

PCPA 14 4

Paxinos et al. (1977). Pharmacology, Biochemistry, Behavior, 6, 439-447.

Page 16: Neuropharmacology: Affective Disorders

5-HT & Aggression• muricide: mouse killing• PCPA: aggression• PCPA + 5-HTP: no

aggression

Paxinos et al. (1977). Pharmacology, Biochemistry, Behavior, 6, 439-447.

Page 17: Neuropharmacology: Affective Disorders

Serotonergic Projects

• Cell bodies in Raphe

• Projections throughout CNS

Page 18: Neuropharmacology: Affective Disorders

5-HT Functions

Spinal Cord Sexual dysfunction

Brain stem Nausea

Modified from Stahl (2001) p. 182

Page 19: Neuropharmacology: Affective Disorders

5-HT Functions

Limbic Anxiety

Brain stem Insomnia

Modified from Stahl (2001) p. 182

Page 20: Neuropharmacology: Affective Disorders

5-HT Functions

Frontal Cortex Mood

Hypothalamus Appetite (Bulimia?)

Modified from Stahl (2001) p. 182

Page 21: Neuropharmacology: Affective Disorders

Fenfluramine• Fenfluramine is a 5-HT releaser that was used

with phentermine for weight control• Animal studies indicate fenfluramine causes 5-HT

axotomy• Methods: Former fenfluramine users (N=15) and

controls (N=17) completed PET imaging

McCann et al. (2007). Molecular Imaging & Biology, 9, 151-157.

Page 22: Neuropharmacology: Affective Disorders

5-HT Receptors

Postsynaptic1A1B2A2C4567

Presynaptic1A

Page 23: Neuropharmacology: Affective Disorders

5-HT1A Agonist: 8-OH-DPAT

• Example#1: Rats received MDMA from age 35 to 60• A 8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tetralin)

challenge was administered at age 67

Piper et al. (2006) JPET, 317, 838-849.

Page 24: Neuropharmacology: Affective Disorders

5-HT2A Agonist: DOI

• Example #2: Rats received MDMA from age 35 to 60

• A DOI (di-methoxy-4-iodophenyl)-2-aminopropane) challenge was administered at age 67

Biezonski et al. (2009) Brain Research, 1252, 87-93.

Page 25: Neuropharmacology: Affective Disorders

MAO-Is

• Monoamine Oxidase (MAO) is an enzyme that breaks down 5-HT, NE, & DA

Page 26: Neuropharmacology: Affective Disorders

MAO-Is

• Monoamine Oxidase (MAO) is an enzyme that breaks down 5-HT, NE, & DA; peak use in 1970s

• Food Interactions: – Tyramine: amino acid breakdown product of

tyrosine, doesn’t cross BBB but causes norepinephrine release

– Tyramine rich foods (aged cheese, beer, wine) + MAO-I results in increased blood pressure & headaches (“cheese effect”)

Page 27: Neuropharmacology: Affective Disorders

MAO-Is

• Monoamine Oxidase (MAO) is an enzyme that breaks down 5-HT, NE, & DA

• Food Interactions: tyramine foods (aged cheese, beer, wine) results in increased norepinephrine (blood pressure)

• Drug Interactions: increased activity of drugs that elevated 5-HT, NE, DA (cocaine, hypericum, ritalin)

• 1st generation were irreversible inhibitors (1960s), 2nd generation are reversible inhibitors

Page 28: Neuropharmacology: Affective Disorders

Tricyclic Antidepressants

• Developed from antipsychotic drugs• Have 3 ringed structure

Page 29: Neuropharmacology: Affective Disorders

SERT & NET Blockade+

Page 30: Neuropharmacology: Affective Disorders

Serotonin Reuptake Inhibitors

• Prozac (fluoxetine) was the original SRI• Greater affinity for SERT than NET• Not Selective (sigma receptors, CYP2D6)• Anorgasmia

Page 31: Neuropharmacology: Affective Disorders

ComparisonMAO-Is TCA SSRIs

Efficacy Moderate Moderate Low

Side-effects “cheese effect”, many drug interactions

orthostatic hypertension, OD

Sexual, DiscontinuationSyndrome

Prevalence very low low high

Mechanism 5-HT, NE, DA 5-HT & NE 5-HT

Therapeutic Lag Yes Yes Yes

Page 32: Neuropharmacology: Affective Disorders

Other Mechanisms of Antidepressants

• 5-HT2

• Intracellelar (e.g. cAMP)• Brain Derived Neurotrophic Factor

Page 33: Neuropharmacology: Affective Disorders

Cortisol

• The Hypothalamus-Pituitary-Adrenal (HPA) axis control release of the stress hormone cortisol.

• As many as half of depressed patients show elevations in cortisol. Drugs that turn off the HPA axis are ineffective.

Belmaker & Agam (2008). New England Journal of Medicine, 358, 55-68.

Page 34: Neuropharmacology: Affective Disorders

Structural Changes following Elevated Cortisol?

• Rat research indicate that persistent increases in cortisol are toxic to hippocampal neurons.

• Studies examining the volume of the hippocampus in MDD were inconsistent.• A meta-analysis showed that the left (-4.5%) and right hippocampus (-4.0%)

showed reductions.

Cole et al. (2011). J of Affective Dis 134, 483-487.

Page 35: Neuropharmacology: Affective Disorders

Antidepressants & Neurogenesis

• New neurons are produced in the hippocampus in adults

ECS: electroconvulsive therapy; TCP: trancyclpromine (MAO-I), or Reboxetine (SNRI)

Mahlberg (2000). J Neurosciece, 20, 9104-9110.

Page 36: Neuropharmacology: Affective Disorders

Electroconvulsive Therapy

• The most effective treatment for MDD (especially high suicide risk)

• Controversial!• Potential memory loss• George, David T. (2011). Electroconvulsive therapy. Starts at

54:50: http://videocast.nih.gov/Summary.asp?File=16674

Page 37: Neuropharmacology: Affective Disorders

Cognitive Behavioral Therapy

• Short, evidence based, therapy• Developed by Aaron T. Beck• Instruction in how thoughts & feelings

influence behavior

1921-

Page 38: Neuropharmacology: Affective Disorders

CBT + Medication• Patients randomized to receive Nefazodone (5-

HT2A/1 antagonist), CBT, or both for 3 months

Nef CBT Nef +CBTCompleters 69.5% 72.2% 76.5%

No Response 44% 48% 15%Remission 22% 24% 42%

Keller et al (2000). New England J of Medicine, 342, 1462-1470.

Page 39: Neuropharmacology: Affective Disorders

Diagnosis of Bipolar

• Bipolar I: – manic episode– depression not

required– not due to

recreational drugs

• Bipolar II:– Hypomanic Episode– major depressive episode– not due to recreational

drugs

Page 40: Neuropharmacology: Affective Disorders

Example of Mania

• Lifetime prevalence: 1% • 1st Minute:

http://www.youtube.com/watch?v=rcl09ztmoDw

Page 41: Neuropharmacology: Affective Disorders

Moreno, C. et al. (2007). Arch Gen Psychiatry, 64, 1032-1039.

National trends in visits with a diagnosis of bipolar disorder as a percentage of total office-based visits by youth (aged 0-19 years) and adults (aged >= 20 years)

Page 42: Neuropharmacology: Affective Disorders

Bipolar Disorder

Many great writers, poets, and composers suffered from bipolar disorder.

During their manic phase creativity surged, but not during their depressed

phase.

Whitman Wolfe Clemens Hemingway

Bettm

ann/ Corbis

George C

. Beresford/ H

ulton Getty P

ictures Library

The G

ranger Collection

Earl T

heissen/ Hulton G

etty Pictures L

ibrary

Page 43: Neuropharmacology: Affective Disorders

Treatment

• Lithium carbonate (Li2CO3)• John Cade, Australian psychiatrist, on giving

lithium to guinea pigs:– “After a latent period of about two-hours, the animals, although fully conscious

became extremely lethargic and unresponsive to stimuli for one to two hours before once again becoming timid and active. Those who have experimented with guinea pigs know to what extent a ready startle reaction is part of their makeup. It was even more startling to find that after the injection of a solution of lithium carbonate they could be turned on their backs and that, instead of the usual frantic righting behavior, they merely lay there and gazed placidly back at him.”

Page 44: Neuropharmacology: Affective Disorders

Depression & Pregnancy

• Drug treatment & pregnancy is a tough decision.

• Depression may also occur Post-partum.

Payne, Jenifer L. (2011). Clinical care of Major Depression during pregnancy. Starts at 31:20: http://videocast.nih.gov/Summary.asp?File=16674


Related Documents